| DAA626 |
Essential (primary) hypertension and hypertensive renal disease |
Pathological |
heart, kidney |
Human |
— |
SeriesMorbidity |
|
| DAA1968 |
Dnmt3a mRNA expression decrease |
Molecular |
heart |
Mouse |
Dnmt3a |
— |
|
| DAA617 |
Diseases of heart |
Pathological |
heart |
Human |
— |
SeriesMorbidity |
|
| DAA2021 |
Diminution in the resting cardiac output |
Physiological |
heart |
Human |
— |
— |
|
| DAA1022 |
Coronary heart disease (Male) |
Pathological |
heart |
Human |
— |
SeriesIncidence |
|
| DAA1023 |
Coronary heart disease (Female) |
Pathological |
heart |
Human |
— |
SeriesIncidence |
|
| DAA709 |
Coronary artery disease incidence increases |
Pathological |
heart, artery |
Human |
— |
— |
|
| DAA704 |
Cellular hypertrophy in left ventricular wall |
Physiological |
left ventricle |
Human |
— |
— |
|
| DAA713 |
Cardiac index decreased |
Physiological |
heart |
Human |
— |
— |
|
| DAA624 |
Atherosclerotic cardiovascular disease |
Pathological |
heart |
Human |
— |
SeriesMorbidity |
|
| DAA1963 |
Alox5 arachidonate 5-lipoxygenase (5-LOX) promoter methylation increase |
Molecular |
heart |
Mouse |
Alox5 |
— |
|
| DAA1965 |
Alox5 arachidonate 5-lipoxygenase (5-LOX) mRNA expression increase |
Molecular |
heart |
Mouse |
Alox5 |
— |
|
| DAA1969 |
Alox5 arachidonate 5-lipoxygenase (5-LOX) mRNA expression decrease |
Molecular |
heart |
Mouse |
Alox5 |
— |
|
| DAA618 |
Acute rheumatic fever and chronic rheumatic heart diseases |
Pathological |
heart, skin, brain |
Human |
— |
SeriesMorbidity |
|
| DAA622 |
Acute myocardial infarction |
Pathological |
heart |
Human |
— |
SeriesMorbidity |
|